文献速递肾癌与肾肿瘤

肾髓质癌患者的管理与结局:一项多中心协作研究

Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.
PubMed 文献 · BJU Int · 2016-12-09

这项多中心协作研究纳入2000—2015年北美和法国8家学术机构收治的52例肾髓质癌患者,中位年龄28岁,94%为III/IV期。全体中位总生存期13.0个月;接受肾切除术者中位总生存期16.4个月,优于仅接受全身治疗者的7.0个月(P < 0.001)。化疗客观缓解率29%,靶向治疗无客观缓解。

要点

  • 肾髓质癌预后差,全体中位总生存期仅13.0个月。
  • 肾切除术组中位总生存期16.4个月,优于仅全身治疗组的7.0个月(P < 0.001)。
  • 化疗45例中13例(29%)客观缓解;靶向治疗28例无客观缓解。

核心结论

  • 肾髓质癌预后差,化疗可提供姑息治疗且仍是主要治疗手段,但不足20%的患者生存超过24个月,凸显开发更有效疗法的必要性。
  • 本研究中肾切除术与改善的总生存期相关。

研究设计与样本

  • 研究纳入2000—2015年在北美和法国8家学术机构治疗的肾髓质癌患者。
  • 采用Kaplan-Meier法估计总生存期(从肾髓质癌初诊至死亡日期),采用Cox回归分析确定总生存期的预测因素。

主要发现

  • 共识别52例患者(37例男性),诊断时中位(范围)年龄28(9-48)岁,49例(94%)为III/IV期。
  • 全体患者中位总生存期为13.0个月,38例(75%)接受肾切除术。
  • 肾切除术组中位总生存期16.4个月,优于仅接受全身治疗组的7.0个月(P < 0.001)。
  • 45例接受化疗,其中13例(29%)客观缓解;28例接受靶向治疗,中位治疗持续时间8周,无客观缓解。
  • 仅7例(13%)生存超过24个月。

临床怎么用

  • 化疗可提供姑息治疗,且仍是肾髓质癌的主要治疗手段。
  • 本研究中肾切除术与改善的总生存期相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the management strategies and outcomes of patients with renal medullary carcinoma (RMC) and characterise predictors of overall survival (OS). PATIENTS AND METHODS: RMC is a rare and aggressive malignancy that afflicts young patients with sickle cell trait; there are limited data on management to date. This is a study of patients with RMC who were treated in 2000-2015 at eight academic institutions in North America and France. The Kaplan-Meier method was used to estimate OS, measured from initial RMC diagnosis to date of death. Cox regression analysis was used to determine predictors of OS. RESULTS: In all, 52 patients (37 males) were identified. The median (range) age at diagnosis was 28 (9-48) years and 49 patients (94%) had stage III/IV. The median OS for all patients was 13.0 months and 38 patients (75%) had nephrectomy. Patients who underwent nephrectomy had superior OS compared to patients who were treated with systemic therapy only (median OS 16.4 vs 7.0 months, P < 0.001). In all, 45 patients received chemotherapy and 13 (29%) had an objective response; 28 patients received targeted therapies, with 8-week median therapy duration and no objective responses. Only seven patients (13%) survived for >24 months. CONCLUSIONS: RMC carries a poor prognosis. Chemotherapy provides palliation and remains the mainstay of therapy, but <20% of patients survive for >24 months, underscoring the need to develop more effective therapy for this rare tumour. In this study, nephrectomy was associated with improved OS.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Shah AY, Karam JA, Malouf GG, et al. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2016. PMID: 27860149. doi:10.1111/bju.13705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。